Tissue Regenix Group plc is a United Kingdom-based international medical technology company. The Company is focused on the development of regenerative products utilizing its two platform technologies, such as dCell and BioRinse. The dCell platform addresses soft tissue needs and BioRinse platform provides sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. Its dCell technology removes deoxyribonucleic acid (DNA) and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold, which is not rejected by the patient's body and can then be used to repair diseased or damaged body parts. Its BioRinse technology is primarily utilized to provide a natural bone filler solution, tested for osteoinductivity, which can stimulate and regenerate native bone growth. Its CellRight Technologies is engaged in the development of osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease.